Group 1 - The major shareholder Chen Dekang, holding 11.67% of the shares, plans to reduce his stake by up to 7.5185 million shares, which is no more than 2% of the company's total share capital, within three months after 15 trading days from the announcement date [1] - The company's wholly-owned subsidiary, Zhejiang Shapu Health Management Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of a new drug, hydrochloride pilocarpine eye drops, which is intended for the treatment of presbyopia in adults [1]

证券代码：603168 证券简称：莎普爱思 公告编号：2025-049 浙江莎普爱思药业股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东的基本情况： 截至 2025 年 9 月 4 日，浙江莎普爱思药业股份有限公司（以下简称"公 司"、"莎普爱思"）大股东陈德康先生持有莎普爱思无限售条件流通股 43,871,004 股，占莎普爱思总股本的 11.67%。 减持计划的主要内容 陈德康先生因个人资金需求，计划自本公告披露之日起 15 个交易日后的 3 个月内，即 2025 年 9 月 25 日至 2025 年 12 月 24 日，通过集中竞价交易方式减 持的股份数量不超过 3,759,250 股，即不超过公司总股本的 1.00%；自公告披露 之日起 15 个交易日后的 3 个月内，通过大宗交易方式减持的股份数量不超过 3,759,250 股，即不超过公司总股本的 1.00%。陈德康先生计划减持数量合计不 超过 7,518,500 股，即不超过公司总股本的 2.00% ...

证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-050 浙江莎普爱思药业股份有限公司 关于全资子公司获得盐酸毛果芸香碱滴眼液 临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江莎普爱思药业股份有限公司（以下简称"公司"）全资子公司浙 江莎普健康管理有限公司获得国家药品监督管理局核准签发的关于盐酸毛果芸 香碱滴眼液的《药物临床试验批准通知书》（通知书编号：2025LP02246），公 司拟于条件具备后开展临床试验。现将相关情况公告如下： 一、药物的基本情况 药品名称：盐酸毛果芸香碱滴眼液 剂型：眼用制剂 注册分类：化学药品3类 申请人：浙江莎普健康管理有限公司 申请事项：临床试验 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，同意 开展临床试验。 二、药物的其他情况 本品适用于治疗成人老花眼。 截至本公告披露日，盐酸毛果芸香碱滴眼液项目累计研发投入约644.57万元 人民币。 三、风险提示 根据我国药品注册相关的法律法规要求，药品在获得药物临床试验批准通知 书 ...

莎普爱思(603168.SH)公告称，大股东陈德康因个人资金需求，计划自公告披露之日起15个交易日后的3 个月内，通过集中竞价和大宗交易方式减持不超过7,518,500股，即不超过公司总股本的2.00%。减持期 间为2025年9月25日至2025年12月24日。减持价格不低于公司首次公开发行股票的发行价。 ...

智通财经APP讯，莎普爱思(603168.SH)发布公告，陈德康先生因个人资金需求，计划自公告披露之日 起15个交易日后的3个月内，减持数量合计不超过751.85万股，即不超过公司总股本的2%。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of a new eye drop product aimed at treating presbyopia in adults [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Zhejiang Shapu Health Management Co., Ltd., has obtained the clinical trial approval notice for the drug, with the notice number 2025LP02246 [1] - The company plans to initiate clinical trials once conditions are met [1] Group 2: Financial Investment - As of the announcement date, the total research and development investment for the pilocarpine hydrochloride eye drops project amounts to approximately 6.4457 million RMB [1]

Core Viewpoint - The company, ShaPu AiSi (603168.SH), has received approval from the National Medical Products Administration for clinical trials of a new eye drop product aimed at treating presbyopia in adults [1] Group 1: Company Developments - ShaPu AiSi's wholly-owned subsidiary, Zhejiang ShaPu Health Management Co., Ltd., has obtained the "Drug Clinical Trial Approval Notice" for the drug, which is identified as hydrochloride pilocarpine eye drops [1] - The company plans to initiate clinical trials once conditions are met [1] - As of the announcement date, the total research and development investment for the hydrochloride pilocarpine eye drops project has reached approximately 6.4457 million RMB [1]

Core Points - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Sulfate Terbutaline Nebulization Solution from the National Medical Products Administration [1][4] - The approved drug is indicated for alleviating bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [2] - The total R&D investment for this drug has reached approximately 5.0111 million RMB [3] Drug Registration Details - Drug Name: Sulfate Terbutaline Nebulization Solution [1] - Dosage Form: Inhalation preparation [1] - Specification: 2ml: 5mg [1] - Registration Classification: Chemical drug category 4 [1] - Approval Number: National Drug Approval Code H20255228 [1] - License Holder: Zhejiang Shapuaisi Pharmaceutical Co., Ltd. [1] - Approval Conclusion: The drug meets the registration requirements as per the Drug Administration Law of the People's Republic of China [1] Impact on the Company - The approval of the Sulfate Terbutaline Nebulization Solution will enrich the company's product portfolio and optimize its product layout [4] - Future production and sales of the drug are subject to uncertainties influenced by pharmaceutical industry policies, bidding procurement, and market environment changes [4]

Group 1 - The company has received the Drug Registration Certificate for Sulbutamol Nebulization Solution, which is classified as a chemical drug of category 4 [1][2] - The drug is indicated for the relief of bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [1] - The total R&D investment for this drug has reached approximately 5.0111 million RMB [2] Group 2 - The approval of the drug will enrich the company's product portfolio and optimize its product layout [2] - Future production and sales of the drug are subject to uncertainties due to factors such as pharmaceutical industry policies, bidding procurement, and market environment changes [2]

Core Viewpoint - The company, Shapuaisi, has received the drug registration certificate for Sulfate Terbutaline aerosol inhalation solution from the National Medical Products Administration [2] Group 1 - The announcement was made on the evening of September 2 [2] - The drug is intended for aerosol inhalation use [2]